A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
IPSEN operates in the Drug Manufacturers - Specialty & Generic industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 3.9B | 3.9B | 3.6B | 3.3B | 3.2B | 3.1B |
| Net Income | 374M | 374M | 700M | 682M | 763M | - |
| EPS | $4.48 | $4.48 | $8.39 | $7.52 | $8.93 | $7,544.81 |
| Free Cash Flow | 989M | 989M | 940M | 1.0B | 941M | 792M |
| ROIC | 11.7% | 8.8% | 17.7% | 19.1% | 25.9% | 17.6% |
| Gross Margin | 82.7% | 82.7% | 82.7% | 83.3% | 84.0% | 81.7% |
| Debt/Equity | 0.00 | 0.18 | 0.23 | 0.20 | 0.24 | 0.36 |
| Dividends/Share | $1.30 | $1.30 | $1.30 | $1.26 | $1.16 | - |
| Operating Income | 537M | 537M | 886M | 769M | 973M | 603M |
| Operating Margin | 13.9% | 13.9% | 24.7% | 23.1% | 30.0% | 19.5% |
| ROE | 8.3% | 8.6% | 18.2% | 20.2% | 26.9% | - |
| Shares Outstanding | 83M | 83M | 83M | 90M | 85M | - |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 3.1B | 3.2B | 3.3B | 3.6B | 3.9B | 3.9B |
| Gross Margin | 81.7% | 84.0% | 83.3% | 82.7% | 82.7% | 82.7% |
| R&D | -466M | -501M | -469M | -672M | -742M | -742M |
| SG&A | 2.4B | 2.3B | 2.5B | 2.8B | N/A | N/A |
| EBIT | 603M | 973M | 769M | 886M | 537M | 537M |
| Op. Margin | 19.5% | 30.0% | 23.1% | 24.7% | 13.9% | 13.9% |
| Net Income | N/A | 763M | 682M | 700M | 374M | 374M |
| Net Margin | N/A | 23.5% | 20.5% | 19.5% | 9.7% | 9.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | 17.6% | 25.9% | 19.1% | 17.7% | 8.8% | 11.7% |
| ROE | N/A | 26.9% | 20.2% | 18.2% | 8.6% | 8.3% |
| ROA | N/A | 14.1% | 11.6% | 11.0% | 5.4% | 5.4% |
| Cash Flow | ||||||
| Op. Cash Flow | 886M | 1.1B | 1.0B | 940M | 989M | 989M |
| Free Cash Flow | 792M | 941M | 1.0B | 940M | 989M | 989M |
| Owner Earnings | 860M | 1.0B | 995M | 907M | 957M | 957M |
| CapEx | 93M | 113M | 0 | 0 | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | 10.6% | 10.7% | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 96M | 98M | 105M | 108M | 108M | 108M |
| Dividend Yield | N/A | 1.2% | 1.1% | 1.1% | 1.1% | 0.8% |
| Share Buybacks | 42M | 51M | 11M | 43M | 36M | 36M |
| Buyback Yield | 0.0% | 0.6% | 0.1% | 0.4% | 0.4% | 0.3% |
| Stock-Based Comp | 26M | 32M | 28M | 33M | 32M | 32M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | 137M | -179M | -529M | 373M | 80M | -733M |
| Cash & Equiv. | 738M | 961M | 1.2B | 574M | 733M | 733M |
| Long-Term Debt | 875M | 782M | 702M | N/A | N/A | N/A |
| Debt/Equity | 0.36 | 0.24 | 0.20 | 0.23 | 0.18 | 0.00 |
| Interest Coverage | 19.4 | 34.8 | N/A | N/A | N/A | N/A |
| Equity | 2.4B | 3.2B | 3.5B | 4.2B | 4.5B | 4.5B |
| Total Assets | 5.0B | 5.9B | 5.9B | 6.9B | 7.0B | 7.0B |
| Total Liabilities | 2.5B | 2.7B | 2.4B | 2.7B | 2.4B | 2.4B |
| Intangibles | N/A | N/A | N/A | 2.9B | 2.7B | 2.7B |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 420M | 856M | 1.1B | 295M | 557M | 557M |
| Current Assets | 1.8B | 2.3B | 2.5B | 2.1B | 2.2B | 2.2B |
| Current Liabilities | 1.4B | 1.4B | 1.4B | 1.8B | 1.6B | 1.6B |
| Per Share Data | ||||||
| EPS | 7,544.81 | 8.93 | 7.52 | 8.39 | 4.48 | 4.48 |
| Owner EPS | N/A | 12.08 | 11.06 | 10.97 | 11.57 | 11.57 |
| Book Value | N/A | 38.26 | 39.15 | 50.20 | 54.60 | 54.60 |
| Cash Flow/Share | N/A | 12.45 | 11.37 | 11.36 | 11.95 | 4.52 |
| Dividends/Share | N/A | 1.16 | 1.26 | 1.30 | 1.30 | 1.30 |
| Shares Out. | N/A | 84.6M | 89.9M | 82.7M | 82.8M | 82.8M |
| Valuation | ||||||
| P/E Ratio | 0.0 | 10.9 | 13.9 | 14.2 | 25.7 | 37.1 |
| P/FCF | N/A | 8.7 | 9.2 | 10.5 | 9.6 | 13.9 |
| EV/EBIT | 0.2 | 8.3 | 11.5 | 11.6 | 17.9 | 24.3 |
| Price/Book | N/A | 2.5 | 2.7 | 2.4 | 2.1 | 3.0 |
| Price/Sales | N/A | 2.5 | 2.8 | 2.7 | 2.5 | 3.6 |
| FCF Yield | N/A | 11.4% | 10.9% | 9.5% | 10.4% | 7.2% |
| Market Cap | 0 | 8.2B | 9.4B | 9.9B | 9.5B | 13.8B |
| Avg. Price | 84.54 | 95.37 | 102.91 | 119.76 | 118.84 | 166.40 |
| Year-End Price | 86.28 | 97.24 | 104.39 | 119.29 | 115.09 | 166.40 |
IPSEN passes 3 of 9 quality checks, indicating weak fundamentals.
IPSEN trades at 37.1x trailing earnings, compared to its 15-year median P/E of 13.9x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 13.9x vs a median of 9.4x. The company's 5-year average ROIC is 17.8% with a gross margin of 82.9%. Total shareholder yield (dividends + buybacks) is 1.0%. At current prices, the estimated annualized return to fair value is +1.0%.
IPSEN (IPN-PA) has a current P/E ratio of 37.1, compared to its historical median P/E of 13.9. The stock is currently considered Expensive based on its historical valuation range.
IPSEN (IPN-PA) has a 5-year average return on invested capital (ROIC) of 17.8%. This indicates strong capital allocation and a potential competitive advantage.
IPSEN (IPN-PA) has a market capitalization of $13.8B. It is classified as a large-cap stock.
Yes, IPSEN (IPN-PA) pays a dividend with a trailing twelve-month yield of 0.78%. The company also returns capital through share buybacks, with a buyback yield of 0.26%.
Based on historical P/E analysis, IPSEN (IPN-PA) appears expensive. The current P/E of 37.1 is 167% above its historical median of 13.9. The estimated fair value CAGR (P/E method) is -8.2%.
IPSEN (IPN-PA) operates in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.
IPSEN (IPN-PA) reported annual revenue of $3.9 billion in its most recent fiscal year, based on SEC EDGAR filings.
IPSEN (IPN-PA) has a net profit margin of 9.7%. This is a modest margin.
IPSEN (IPN-PA) generated $989 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
IPSEN (IPN-PA) has a debt-to-equity ratio of 0.18. This indicates a conservatively financed balance sheet.
IPSEN (IPN-PA) reported earnings per share (EPS) of $4.48 in its most recent fiscal year.
IPSEN (IPN-PA) has a return on equity (ROE) of 8.6%. This indicates moderate shareholder returns.
IPSEN (IPN-PA) has a 5-year average gross margin of 82.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for IPSEN (IPN-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
IPSEN (IPN-PA) has a book value per share of $54.60, based on its most recent annual SEC filing.